Beth Camhi-Greenberg
Adult Health · Oakland Park, FLNPI 1215363593
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 41.2% of the total. Reporting peaked in 2021 at $8,862 and has fallen 82.6% since, to $1,540 in 2025. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $41.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$7K
- Bayer$2K
- Novo Nordisk$2K
- Senseonics, Incorporated$1K
- Lilly USA, LLC$1K
- Sanofi-aventis U.S. LLC$796
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$8,30047%
- Travel & lodging$1,1807%
- Food & beverage$8,15046%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 26 | $7,281 |
| Bayer | 22 | $1,886 |
| Novo Nordisk | 91 | $1,632 |
| Senseonics, Incorporated | 3 | $1,200 |
| Lilly USA, LLC | 53 | $1,128 |
| Sanofi-aventis U.S. LLC | 29 | $796 |
| AstraZeneca | 24 | $715 |
| Amgen(2 entities) | 49 | $625 |
| Corcept Therapeutics | 21 | $362 |
| Amarin Pharma, Inc. | 15 | $283 |
| Antares Pharma, Inc. | 11 | $252 |
| Mannkind Corporation | 9 | $191 |
| Insulet Corporation | 9 | $190 |
| Xeris Pharmaceuticals, Inc. | 7 | $146 |
| Novartis | 8 | $146 |
| Boehringer Ingelheim | 7 | $141 |
| Dexcom, Inc. | 8 | $140 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| Ascensia Diabetes Care US Inc. | 3 | $55 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Halozyme Inc | 2 | $42 |
| Roche Diabetes Care, Inc. | 2 | $40 |
| Medtronic | 2 | $35 |
| Sequel Med Tech, LLC | 2 | $34 |
| Recordati_rare_diseases_inc. | 1 | $30 |
| Abbott | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $23 |
| Merck | 1 | $23 |
| AbbVie | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Embecta Corp. | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Avvisto Therapeutics, LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,693 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 249 | $341,034 |
| Tresiba Flextouch U-200Insulin Degludec | 137 | $146,623 |
| MounjaroTirzepatide | 111 | $141,505 |
| JardianceEmpagliflozin | 78 | $102,107 |
| FarxigaDapagliflozin Propanediol | 64 | $64,815 |
| VascepaIcosapent Ethyl | 61 | $51,975 |
| TrulicityDulaglutide | 31 | $49,694 |
| Repatha SureclickEvolocumab | 53 | $47,699 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $44,595 |
| RybelsusSemaglutide | 29 | $35,051 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $32,658 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $28,983 |
| Novolog FlexpenInsulin Aspart | 87 | $28,726 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $27,387 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $22,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,632 | $382,075296 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,128 | $193,556155 claims |
| Boehringer IngelheimJardiance, Tradjenta | $141 | $121,90897 claims |
| AstraZenecaFarxiga | $715 | $64,81564 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $796 | $22,56112 claims |
| MerckJanuvia | $23 | $19,48612 claims |
| AmgenProlia | $625 | $19,31411 claims |
| BayerKerendia | $1,886 | $17,09817 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $53 | $5,286140 claims |
| AbbVieSynthroid | $19 | $2,35517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Oakland Park
- Timothy McDowellOakland Park$16K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.